Second surgery for recurrent glioblastoma: A concise overview of the current literature

[1]  C. Woernle,et al.  Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. , 2015, World neurosurgery.

[2]  Emmanuel Mandonnet,et al.  IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients , 2015, PloS one.

[3]  M. Sughrue,et al.  Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework. , 2015, Neurosurgical focus.

[4]  H. Seol,et al.  Outcome of salvage treatment for recurrent glioblastoma , 2015, Journal of Clinical Neuroscience.

[5]  A. Brandes,et al.  The effect of re-operation on survival in patients with recurrent glioblastoma. , 2015, Anticancer research.

[6]  M. Berger,et al.  Reoperation for recurrent high-grade glioma: a current perspective of the literature. , 2014, Neurosurgery.

[7]  K. Zaghloul,et al.  Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. , 2014, Journal of neurosurgery.

[8]  N. Zamboglou,et al.  Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm , 2014, Journal of Neuro-Oncology.

[9]  Peter Nakaji,et al.  An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. , 2014, Journal of neurosurgery.

[10]  E. Hattingen,et al.  Benefit of tumor resection for recurrent glioblastoma , 2014, Journal of Neuro-Oncology.

[11]  W. Mason,et al.  Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression , 2014, Journal of Neuro-Oncology.

[12]  Hans Skovgaard Poulsen,et al.  Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution , 2013, BMC Cancer.

[13]  G. Reifenberger,et al.  Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations , 2013, Clinical Cancer Research.

[14]  H. Seol,et al.  A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. , 2013, Neuro-oncology.

[15]  G. Maira,et al.  The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma , 2013, Clinical Neurology and Neurosurgery.

[16]  Tomas Garzon-Muvdi,et al.  Histopathological correlates with survival in reoperated glioblastomas , 2013, Journal of Neuro-Oncology.

[17]  G. Gallia,et al.  Multiple resections for patients with glioblastoma: prolonging survival. , 2013, Journal of neurosurgery.

[18]  J. Brøgger,et al.  γ knife surgery versus reoperation for recurrent glioblastoma multiforme. , 2012, World neurosurgery.

[19]  Mitchel S Berger,et al.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. , 2012, Journal of neurosurgery.

[20]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[21]  Michael Weller,et al.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. , 2012, Neuro-oncology.

[22]  A. Moiyadi,et al.  Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. , 2012, Neurology India.

[23]  Susan M. Chang,et al.  Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment , 2012, Neurosurgery.

[24]  Mitchel S Berger,et al.  An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.

[25]  W. Franklin,et al.  Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. , 2010, International journal of radiation oncology, biology, physics.

[26]  D. Scheie,et al.  Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme , 2010, Acta neurologica Scandinavica.

[27]  P. Black,et al.  Scale to predict survival after surgery for recurrent glioblastoma multiforme. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Xin-gang Li,et al.  Survival analysis of 205 patients with glioblastoma multiforme: Clinical characteristics, treatment and prognosis in China , 2009, Journal of Clinical Neuroscience.

[29]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[30]  Henry Brem,et al.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma. , 2009, Journal of neurosurgery.

[31]  W. Vandertop,et al.  Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. , 2008, Surgical neurology.

[32]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[33]  G. Broggi,et al.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? , 2008, Journal of Neuro-Oncology.

[34]  D. Caldiroli,et al.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. , 2008, Neuro-oncology.

[35]  M. Shigemori,et al.  Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. , 2007, Surgical neurology.

[36]  H. Mehdorn,et al.  Glioblastoma—the consequences of advanced patient age on treatment and survival , 2006, Neurosurgical Review.

[37]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[38]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[40]  Wei Huang,et al.  Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. , 2003, Journal of neurosurgery.

[41]  M. Bernstein,et al.  The value of reoperation for recurrent glioblastoma. , 1993, Canadian journal of surgery. Journal canadien de chirurgie.

[42]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[44]  B. Tuğcu,et al.  Efficacy of clinical prognostic factors on survival in patients with glioblastoma. , 2010, Turkish neurosurgery.

[45]  Susan M. Chang,et al.  Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. , 2004, Journal of neurosurgery.

[46]  P. Kelly,et al.  Reoperation for recurrent malignant gliomas: what are your indications? , 1997, Surgical neurology.

[47]  A. Brandes,et al.  O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. , 2010, Neuro-oncology.

[48]  R. Mirimanoff,et al.  PREDICTING SURVIVAL OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME : A PROGNOSTIC FACTOR ANALYSIS OF EORTC / NCIC TRIAL 26981-22981 / CE . 3 ( 2 ) author ’ s names , 2008 .